Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

Market Cap	4.72B +70.8%
Revenue (ttm)	1.54B +24.5%
Net Income	99.48M +390.1%
EPS	0.45 +430.9%
Shares Out	220.45M
PE Ratio	47.32
Forward PE	34.02
Dividend	0.05 (0.23%)
Ex-Dividend Date	Jun 25, 2025

Volume	10,358,074
Average Volume	5,981,527
Open	21.40
Previous Close	21.43
Day's Range	21.35 - 22.45
52-Week Range	11.40 - 31.15
Beta	0.46
RSI	55.09
Earnings Date	Apr 25, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 2,404
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603538

Financial Performance

In 2024, SHA:603538's revenue was 1.37 billion, an increase of 12.85% compared to the previous year's 1.22 billion. Earnings were 66.81 million, an increase of 476.64%.